Perfume harassment
This article was originally published in The Rose Sheet
Executive Summary
U.S. District Court for the District of Columbia dismisses pro se complaint filed by man seeking $200 mil. from FDA for agency's incompetence in approving "a steroid perfume that constitutes sexual harassment by those who wear [it]." Smelling the perfume evokes "dirty thoughts," plaintiff claims. Plaintiff himself was a victim of the substance - which "poses as great a threat to society in general as the atom bomb" - losing his job due to perfume's effect over him, according to Oct. 2 statement. In cases where a plaintiff is proceeding in forma pauperis - without the funds to cover the normal costs of a lawsuit - court is obligated to dismiss if complaint fails to state a claim upon which relief may be granted, as in complaint described
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.